ArticleJournal of natural medicines2016
Two new lignans and melanogenesis inhibitors from Schisandra nigra.
Article in Journal of natural medicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Antileishmanial Activity of Lignans, Neolignans, and Other Plant Phenols.Progress in the chemistry of organic natural products · 2021Article
- Functionalized Tyrosinase-Lignin Nanoparticles as Sustainable Catalysts for the Oxidation of Phenols.Nanomaterials (Basel, Switzerland) · 2018Article
- Sesquiterpenoids from the Rhizomes of Homalomena occulta.Natural products and bioprospecting · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An acetone extract from the stems of Schisandra nigra MAX. (Schisandraceae) exhibited significant inhibition of 3-isobutyl-1-methylxanthine (IBMX)-stimulated melanogenesis in murine B16 melanoma F10 cells. Fractionation and purification of the extract led to the isolation of two new tetrahydrofuran-type lignans, (+)-5-methoxyzuonin A (2) and kadlongirin C (3), along with eight known compounds (1, 4-10). The structures of the new compounds were determined by spectroscopic analyses. Of the isolated compounds (1, 3 -10), (+)-zuonin A (1) showed remarkable inhibition of melanogenesis at concentrations without cytotoxicity in B16 melanoma F10 cells. (+)-Zuonin A (1) did not inhibit tyrosinase; however, Western blot analysis revealed that it decreased protein levels of tyrosinase and tyrosinase-related proteins (TRP)-1 and TRP-2 without changing phosphorylation level of cAMP response element-binding protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.